Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

114 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2018-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the effect of moxonidine versus bisoprolol on collagen type 1 C-telopeptide in postmenopausal female patients with arterial hypertension and osteopenia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients

NCT01508325

Hypertension

COMPLETED PHASE4

Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome

NCT04023565

Arterial Hypertension Metabolic Syndrome

UNKNOWN PHASE4

An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])

NCT01079962

Hypertension

COMPLETED PHASE4

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24

NCT00679484

Chronic Heart Failure High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

TERMINATED PHASE3

Morning Versus Bedtime Dosing of Antihypertensive Medication

NCT05089448

Hypertension Blood Pressure Drug Use

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Several experimental studies have demonstrated that moxonidine may lower the activity of Na+- independent Cl-/bicarbonate exchanger (anion exchanger, AE) which plays an essential role in viability of osteoclasts that are crucial for bone resorption. The suppression of AE proteins activity has been proven to inhibit osteoclast activity and reduce bone resorption whereas the moxonidine molecule is known to reduce the AE protein activity. Therefore, the results of experimental studies have shown the ability of moxonidine to inhibit bone resorption through its effect on the osteoclast activity.

Published data contain information on positive effects of beta-blockers on the bone tissue condition. There are data which clearly demonstrate a positive effect of beta-blockers on bone mass.

The proposed trial is a comprehensive study of moxonidine effects on processes of cellular and vascular aging as well as bone metabolism.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteopenia Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moxonidine

0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID

Group Type EXPERIMENTAL

Moxonidine

Intervention Type DRUG

0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D

Bisoprolol

5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID

Group Type ACTIVE_COMPARATOR

Bisoprolol

Intervention Type DRUG

5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Moxonidine

0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D

Intervention Type DRUG

Bisoprolol

5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Physiotens

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Female with age 45 years and older.
2. Postmenopausal (absence of menstrual periods for a minimum of 12 months) at the moment of Informed Consent sign.
3. Arterial hypertension grade I / II per ESH/ESC 2013 guidelines (diastolic pressure ≥ 90 and \<110 mm Hg, systolic pressure ≥140 and \<180 mm Hg).
4. Not achieving BP targets \<140/90 mmHg either during antihypertensive therapy or naive.
5. Absence of moxonidine or bisoprolol treatment at least 6 months before the study
6. Osteopenia of lumbar spine and/or proximal part of the femur (osteoporosis T-score from -1 to -2.5 standard deviations \[SD\]) by X-Ray densitometry.
7. Signed Informed Consent for participation in the study

\-

Exclusion Criteria

1. Hypersensitivity to moxonidine, bisoprolol or any other ingredient of the respective formulations
2. Any Contraindications for moxonidine, bisoprolol
3. Osteoporosis (Т-score below - 2.5 SD).
4. Primary or secondary hyperparathyroidism.
5. Paget's disease of bones.
6. History of low traumatic bone fractures.
7. Malabsorption syndrome.
8. History of gastro-intestinal surgery.
9. Severe disturbance of peripheral circulation.
10. Raynaud's disease.
11. Symptomatic (secondary) hypertension (caused by any primary internal diseases)
12. Morbid obesity (BMI over 40 kg/m2).
13. Symptoms of estrogen deficiency such as hot flushes, nights sweat, vaginal dryness
14. Administration of any hormone-replacement therapy (HRT) or intake of isoflavones
15. Secondary hypogonadism.
16. Sistolic BP ≥180 mm Hg and/or Diastolic BP ≥110 mm Hg.
17. Clinical presentations of cardiovascular disease: coronary heart disease (CHD), history of stroke, transient ischemic attack (TIA), Charcot's syndrome.
18. Severe heart failure.
19. Hemodynamically significant congenital heart disease.
20. Heart rhythm disorders which require permanent use of any antiarrhythmic medications (including β-adrenoblockers and calcium antagonists).
21. Diabetes mellitus of any genesis.
22. Severe liver failure.
23. Severe kidney failure including patients on dialysis
24. Thyroid diseases accompanied by functional disorders (thyrotoxicosis or uncompensated hypothyroidism).
25. Alcohol and drug abuse.
26. Patients with oncological diseases diagnosed within 5 years before IC execution.
27. Inability of the patient to comprehend the essence of the program and to provide his/her consent for participation in the program.
28. Patients with any condition, which in the opinion of the Investigator makes the patient unsuitable for inclusion based on clinical judgment.
29. Corticosteroid therapy
30. Participation in any other clinical study during the whole course of this investigation including participation in a study within 30 days prior to providing the informed consent for this trial

\-

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No